Market access pathways by country

Explore how an innovative medicine moves from approval to patient access.

Selected market

Mainland China

NMPA approval and national reimbursement are distinct. Innovative medicines may enter NRDL negotiation after expert review.

NMPA

NHSA

Provincial medical-insurance authorities

4 decision nodes20 cited sources

For education only — not regulatory, pricing or legal advice.